Please find all related articles below.
Supplying poor and developing countries with medicines at sustainable, reduced prices is one of the most important tools in the fight against major diseases, especially the “Big Three”, namely HIV, TB and malaria. After more than a decade since the Council Regulation (EC) 953/2003 came into force, to avoid trade diversion into the European Union of certain key medicines, stakeholders came together to discuss the overall impact of the Regulation at a workshop on 15 July 2015, (...)
Public health is not just about human diseases, healthcare services or cross-border pandemics. Most of all, health is about people. Giving wider attention to the individual also fits perfectly with the European 2020 vision of ’smart, inclusive and sustainable’ growth for a healthier EU, as highlighted at a recent meeting on ’health literacy in Europe’ organised by STOA - European Parliament Science and Technology Options Assessment - on 1 July 2015.
People are used (...)
An event organised by the CEPS on 13 May 2015 provided an update of the status quo of the General Data Protection Regulation (GDPR) and presented issues under discussion during the Trilogue negotiations. Although the principal focus lay on stimulating dialogue between regulators and SMEs/start-ups, the debate also touched upon some health-related issues such as the development of eHealth as part of the Digital Single Market, and it brought up ethical questions related to the potential uses (...)
Unsurprisingly, mHealth was a hotly debated topic during the 2015 eHealth Week hosted by the Latvian Council Presidency. In addition to the official conference programme, where the mHealth summit uncovered some of the latest developments in this area, the European Commission also organised a stakeholder meeting including industry and civil society representatives to determine the appropriate level of regulation for mHealth at EU level.
European Health Commissioner Vytenis Andriukaitis (...)
Brussels, 11 May 2015 – The 2015 eHealth forum, organised under the auspices of the Latvian Presidency, will discuss the next steps regarding the further roll-out of eHealth in Europe. Mobile smartphone applications in particular have propelled eHealth to centre stage in recent years. As noted in the European Commission’s Green Paper on mobile Health (mHealth) (1), 100,000 health apps are already on the market and it is estimated that 50% of smartphone owners will be using them (...)
EPHA responded to the European Commission consultation on science in transition, emphasizing that epidemiological research should be an important component of the EU’s Horizon 2020 research programme.
The primary focus of health research should be to improve public health and to reduce health inequalities. This includes research on population level interventions: improving the social and environmental determinants of health, understanding health behaviours, promoting continuity of (...)
European Ministers of Health also adopted conclusions on innovation for the benefit of patients at a Council meeting on 1 December 2014. Ministers are calling on national governments and the European Commission to cooperate more closely on the ’life cycle approach’ for new innovative medicines and move ahead with the implementation of health technology assessment.
The Council conclusions highlight the importance of early dialogue between technology developers, regulatory, (...)
Carlos Moedas (age 44) studied engineering at Lisbon University, Portugal and an MBA at Harvard University, USA. He worked for Goldman Sachs and EuroHypo investment bank before returning to Portugal in 2004 to join a property consulting company, and established his own property investment company in 2008. He led negotiations for the Social Democratic Party (PSD) for Portugal’s 2011 State Budget. He was elected as an MP in the same year, and leading implementation of the (...)
28 October 2014, Brussels – MEPs, patients and the European public health community are today asking President-elect Juncker to clarify whether medical devices and health technologies will remain in the directorate for health or not. Fears over patient safety remain as Mr Juncker has so far failed to publicly clarify his ambiguous statement (1) last week to the European Parliament.
Last week’s statement of the European Commission’s President-elect that the competence for (...)
Further to our Joint Letter of 16 September 2014 (1) , we are contacting you again to express our gratitude for your decision (2) to move the competence for medicines and pharmaceutical products back into the hands of the European Commissioner for Health. We firmly believe that this directorate is best placed to ensure a good balance between economic and public health objectives while promoting ‘smart, sustainable and inclusive’ growth for Europe.
28 October 2014, Brussels (...)